Clinical Researchers

Research interests: I am investigating predictors of antithrombotic-associated bleeding. I have an interest in improving the use of eHealth technologies – I am studying the impact of evidence on the utilization of eHealth interventions and am testing a computerized-decision support and documentation system in thrombosis clinics. I also have a collaborative interest in studying the contribution of various pathways to thrombosis of prosthetic valves.

Research interests: I am investigating predictors of antithrombotic-associated bleeding. I have an interest in improving the use of eHealth technologies – I am studying the impact of evidence on the utilization of eHealth interventions and am testing a computerized-decision support and documentation system in thrombosis clinics. I also have a collaborative interest in studying the contribution of various pathways to thrombosis of prosthetic valves.

Co-chairs the International Society of Thrombosis and Hemostasis Subcommittee on Hemostatic Management of Patients with Liver Disease. Actively involved with Thrombosis Canada, specifically, the updating of clinical guides to provide health care providers with evidence-based summaries on commonly encountered thrombosis-related issues. 

Research interests: The efficacy and safety of anticoagulants in special populations, including in patients with drug interactions, renal impairment and liver disease.

Co-chairs the International Society of Thrombosis and Hemostasis Subcommittee on Hemostatic Management of Patients with Liver Disease. Actively involved with Thrombosis Canada, specifically, the updating of clinical guides to provide health care providers with evidence-based summaries on commonly encountered thrombosis-related issues. 

Research interests: The efficacy and safety of anticoagulants in special populations, including in patients with drug interactions, renal impairment and liver disease.

Research interests: My research seeks to improve our understanding of the triggers for thrombosis (including the role of inflammation) and the determinants of variable response to antithrombotic therapies to inform on novel approaches to reduce the burden of thrombosis. Currently, I am developing a research program to understand the role of anti-inflammatory therapy in atherothrombosis.

Trial(s): Principal investigator of the Canadian Institutes of Health Research (CIHR) funded LEADER PAD trial (n=6150 participants).The Low dose colchicine to reduce residual vascular risk in peripheral artery disease trial is a multicenter randomized trial that is conducted by an experienced international collaborative group (Canada, the Netherlands, Australia, UK and US) across a global network of ? 100 sites in ? 10 countries to answer a clinically important question in PAD: In high-risk patients with symptomatic PAD, will anti-inflammatory therapy with low dose colchicine reduce major adverse cardiovascular or limb events (MACE + MALE) when compared to placebo?

Research interests: My research seeks to improve our understanding of the triggers for thrombosis (including the role of inflammation) and the determinants of variable response to antithrombotic therapies to inform on novel approaches to reduce the burden of thrombosis. Currently, I am developing a research program to understand the role of anti-inflammatory therapy in atherothrombosis.

Trial(s): Principal investigator of the Canadian Institutes of Health Research (CIHR) funded LEADER PAD trial (n=6150 participants).The Low dose colchicine to reduce residual vascular risk in peripheral artery disease trial is a multicenter randomized trial that is conducted by an experienced international collaborative group (Canada, the Netherlands, Australia, UK and US) across a global network of ? 100 sites in ? 10 countries to answer a clinically important question in PAD: In high-risk patients with symptomatic PAD, will anti-inflammatory therapy with low dose colchicine reduce major adverse cardiovascular or limb events (MACE + MALE) when compared to placebo?

Fellow of the Canadian Academy of Health Science, past-president of Thrombosis Canada (2013-21) and editor-in-chief of the Canadian Journal of General Internal Medicine.

Research interests: perioperative anticoagulant management and related guideline development; and the prevention, treatment and prognosis of patients with venous thromboembolism.

Fellow of the Canadian Academy of Health Science, past-president of Thrombosis Canada (2013-21) and editor-in-chief of the Canadian Journal of General Internal Medicine.

Research interests: perioperative anticoagulant management and related guideline development; and the prevention, treatment and prognosis of patients with venous thromboembolism.

Research interests: orthopedic thromboprophylaxis, cancer thrombosis, new anticoagulants, anticoagulant monitoring, monitoring hemophilia therapies.

Ongoing trials: EPCAT-3, EXaCT (Evaluating point-of-care anti-Xa coagulation testing)

Research interests: orthopedic thromboprophylaxis, cancer thrombosis, new anticoagulants, anticoagulant monitoring, monitoring hemophilia therapies.

Ongoing trials: EPCAT-3, EXaCT (Evaluating point-of-care anti-Xa coagulation testing)

Research interests: The treatment and prevention of upper extremity deep vein thrombosis (DVT) and the use of direct oral anticoagulants (DOACs) in high-risk populations

Trials: TRIM-Line co-principal investigator, EPCATIII-St. Joseph’s Hospital Site principal investigator

Research interests: The treatment and prevention of upper extremity deep vein thrombosis (DVT) and the use of direct oral anticoagulants (DOACs) in high-risk populations

Trials: TRIM-Line co-principal investigator, EPCATIII-St. Joseph’s Hospital Site principal investigator

Research interests: Population pharmacokinetic for the individualization of Hemophilia treatment: gene therapy for the treatment of hemophilia

Ongoing trials: WAPPS-Hemo; Gene therapy solution for patients with anti-AAV antibodies

Research interests: Population pharmacokinetic for the individualization of Hemophilia treatment: gene therapy for the treatment of hemophilia

Ongoing trials: WAPPS-Hemo; Gene therapy solution for patients with anti-AAV antibodies

Research interests: Optimizing management of venous thromboembolism and non-malignant hematologic disorders including iron deficiency anemia

Research interests: Optimizing management of venous thromboembolism and non-malignant hematologic disorders including iron deficiency anemia

Research interests: Treatment of congenital bleeding disorders, novel therapies for hemophilia and pharmacokinetics of clotting factor concentrates in hemophilia A and B. Is an active clinical trial investigator involved in numerous trials in the field of thrombosis and haemostasis with a specific focus on novel therapies for hemophilia, including gene therapy, FVIII mimetics, coagulation re-balancing agents. His group is very active also in summarizing and disseminating research results and producing high-quality systematic reviews in the field of bleeding disorders.

Research interests: Treatment of congenital bleeding disorders, novel therapies for hemophilia and pharmacokinetics of clotting factor concentrates in hemophilia A and B. Is an active clinical trial investigator involved in numerous trials in the field of thrombosis and haemostasis with a specific focus on novel therapies for hemophilia, including gene therapy, FVIII mimetics, coagulation re-balancing agents. His group is very active also in summarizing and disseminating research results and producing high-quality systematic reviews in the field of bleeding disorders.

Research interests: Oral anticoagulant management, in reversal of direct oral anticoagulants (DOACs), in antiphospholipid syndrome and in bleeding complications.

Ongoing trials: PROXY – management of patients on Xa inhibitors for emergency surgery – principal investigator for the PROXY study (PCC) and chair of the event adjudication committee for ANNEXA-RS (andexanet alfa). Principal investigator for the International Society on Thrombosis and Haemostasis (ISTH) registry on antithrombotic treatment for arterial antiphospholipid syndrome.

Research interests: Oral anticoagulant management, in reversal of direct oral anticoagulants (DOACs), in antiphospholipid syndrome and in bleeding complications.

Ongoing trials: PROXY – management of patients on Xa inhibitors for emergency surgery – principal investigator for the PROXY study (PCC) and chair of the event adjudication committee for ANNEXA-RS (andexanet alfa). Principal investigator for the International Society on Thrombosis and Haemostasis (ISTH) registry on antithrombotic treatment for arterial antiphospholipid syndrome.